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A number of studies have shown that damage to brain structures adjacent to neurogenic
regions can result in migration of new neurons from neurogenic zones into the damaged
tissue. The number of differentiated neurons that survive is low, however, and this has
led to the idea that the introduction of extrinsic signaling factors, particularly neurotrophic
proteins, may augment the neurogenic response to a level that would be therapeutically
relevant. Here we report on the impact of the relatively newly described neurotrophic
factor, Meteorin, when over-expressed in the striatum following excitotoxic injury. Birth-
dating studies using bromo-deoxy-uridine (BrdU) showed that Meteorin did not enhance
injury-induced striatal neurogenesis but significantly increased the proportion of new
cells with astroglial and oligodendroglial features. As a basis for comparison we found
under the same conditions, glial derived neurotrophic factor significantly enhanced
neurogenesis but did not effect gliogenesis. The results highlight the specificity of
action of different neurotrophic factors in modulating the proliferative response to injury.
Meteorin may be an interesting candidate in pathological settings involving damage to
white matter, for example after stroke or neonatal brain injury.
Keywords: forebrain injury, striatum, neurogenesis, oligodendrogenesis, GDNF, brain repair
INTRODUCTION
Meteorin is a member of a newly described family of secreted proteins that also includes the
related protein, Meteorin-like. It is highly expressed in the mammalian brain, throughout mid-
to late-development and is maintained at lower levels in the post-natal brain (Jorgensen et al.,
2009). In adult rodents, Meteorin protein is most conspicuously expressed by Bergmann glia in
the cerebellum, but also more diffusely at lower levels in glia cells throughout the brain. It was
first characterized in vitro for its ability to promote astrocyte differentiation and axon growth in
neurosphere cultures and dorsal root ganglion explants, respectively, (Nishino et al., 2004). Later
studies established that Meteorin’s pro-gliogenic functionality acted on the Jak-STAT3 pathway
(Lee et al., 2010; Sun et al., 2014), although to date, the receptor it functions through remains
unknown.
In vivo studies in rodents demonstrated that after excitotoxic injury to the striatum, endogenous
Meteorin is up-regulated in striatal s100β+ astrocytes (Jorgensen et al., 2011), and has also been
observed in neurons after ischaemic damage (Wang et al., 2012). To explore it’s functional impact in
this setting, subsequent studies demonstrated that over-expression of Meteorin via viral (Jorgensen
et al., 2011) or encapsulated cell (Tornoe et al., 2012) delivery prior to excitotoxic injury resulted
in significantly reduced levels of striatal damage (Jorgensen et al., 2011; Tornoe et al., 2012). More
recently, studies have also begun to investigate the possibility that, in addition to neuroprotection
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of existing circuitry, Meteorin might also act as a survival factor
for newborn neurons generated in response to striatal injury
(Wang et al., 2012).
A number of studies have shown that, following striatal
injury resulting in extensive cell loss, neuroblasts constitutively
generated in the sub-ventricular zone (SVZ) can migrate
into the damaged striatal parenchyma and differentiate into
mature neurons (Arvidsson et al., 2001, 2002; Jin et al.,
2001, 2003, 2006; Parent et al., 2002). The overall survival
of these new neurons is notably poor and well below levels
likely to be required for therapeutic replacement of neurons
lost to the injury. This has motivated studies that investigate
strategies to improve the survival of newborn neurons, for
example through delivery of trophic factors. Topical delivery
of soluble proteins known to influence cell survival, neural
stem cell proliferation and neurogenesis in other disease
models have proven to be robust regulators of these cellular
processes in the context of forebrain injury. Examples of
such factors are Glia-derived neurotrophic factor (GDNF;
Kobayashi et al., 2006), Vascular endothelial growth factor
(VEGF; Sun et al., 2003), along with Noggin and Brain-
derived neurotrophic factor (BDNF; Benraiss et al., 2012) which
have all been shown to positively regulate neurogenesis in
the damaged striatum. The expression of Meteorin during
neural development and in the adult striatum makes it
an interesting candidate in this context. Recently, Wang
et al. (2012) demonstrated that chronic infusion of Meteorin
increased SVZ proliferation and neuroblast migration into the
damaged striatum after medial cerebral artery occlusion in
rats, resulting in increased numbers of surviving newborn
neurons.
Here we sought to characterize the phenotype of new
cells generated in the presence of Meteorin after striatal
damage – including the identity of neuronal and glial subtypes.
Following excitotoxic damage, we found that stable expression
of Meteorin using a lenti-virus resulted in a small increase in
the survival of new neurons which did not reach statistical
significance. To contextualize this impact on neuronal survival,
we also present results from GDNF expression in the same
experimental paradigm, where there was a much larger effect
on neurogenesis in response to injury. The major impact of
Meteorin was in fact to drive gliogenesis, where birth-dating
studies using Bromodeoxyuridine (BrdU) showed that there
was a significant increase in the proportion of new s100β+
astrocytes and Oligodendrocyte transcription factor 2 (Olig2+)
oligodendrocyte progenitors in response to damage to the adult
striatum.
MATERIALS AND METHODS
Ethical Approval
All experimental procedures carried out in this study conform to
the rules set out by the Australian National Health and Medical
Research Council published code of practice and experiments
were approved by the Florey Neuroscience Institutes animal
ethics committee (no. 09-105).
In Vivo Procedures
Adult Sprague−Dawley rats were housed under a 12-h light/dark
cycle with ad libitum access to food and water. Surgery was
performed at 6 weeks of age using age matched animals. Prior
to surgery, rats were deeply anesthetized with isoflurane (5% at
1 L/min) and kept under anesthesia (2−3% at 1 L/min) for the
duration of surgery.
All surgical procedures were performed using a stereotaxic
frame (Kopf, Germany) and intra-striatal delivery was performed
using a fine glass capillary fitted to a 5 µl microsyringe
(SGE Analytical Sciences, Australia). Under deep anesthesia,
all animals received 2 µl of quinolinic acid (QA) solution
(100 nmol/µl in 0.9% saline) injected over 2 min into the striatum
(1.2 mm anterior and 3 mm lateral to bregma and 4 mm below
the dural surface). The cannula was kept in place for 5 min after
injection to minimize back-flow.
Twenty four hours post-injection, all animals underwent a
second round of surgery (setup as previously described) for intra-
striatal lentivirus delivery constructed as previously described
(Jorgensen et al., 2011). Three treatment groups were compared
within this study. Animals received one of either lentivirus
encoding Meteorin (Jorgensen et al., 2011), GDNF (pHsCXW,
NsGene), and GFP (pHsCXW, NsGene) for control animals via
a 1.5 µl solution (1.2 × 105 transforming units total) over
2 min into the striatum (1.2 mm anterior and 3.2 mm lateral
to bregma and 4 mm below the dural surface). All vectors were
under the control of the woodchuck post-regulatory element for
constitutive transgene expression.
To label dividing cells, animals received BrdU (50 mg/kg i.p.
using a 20 mg/ml solution in 0.9% saline) every 12 h for 2 weeks
as previously described (Arvidsson et al., 2002), beginning the
day of lentiviral delivery. Animals were perfused for histological
assessment 4 weeks after BrdU treatment (6 weeks after QA
lesion).
Tissue Preparation
At 6 weeks after surgery, animals under deep anesthesia induced
with isoflurane (5% at 1 L/min), subsequently received a
lethal dose of pentobarbitone. Animals were then transcardially
perfused with 50 ml saline (0.9% w/v) followed by 200–250 ml
paraformaldehyde (PFA; 4% w/v in 0.1 M PBS). The brains were
removed, post-fixed a further 2 h in PFA and cryoprotected in
sucrose (20% w/v in 0.1 M PBS). Brains were sectioned in the
coronal plane in a 1:12 series at a thickness of 30 µm on a freezing
microtome (Leica, Germany).
Immunohistochemistry
Primary antibodies were diluted in a solution of 0.1 M
PBS containing 5% normal serum and 0.5% Triton X-100
(Amereso, USA) and incubated with sections overnight at room
temperature. Prior to the addition of the secondary antibody
solution, the sections were blocked with 5% normal serum for
0.5−1 h. Secondary antibodies were diluted in a solution of 0.1 M
PBS containing 2% normal serum and 0.5% Triton X-100 and
incubated for 2 h at room temperature. For fluorescent analysis,
secondary antibodies were conjugated to Dylight Fluorophores
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488, 549, or 647 and slide-mounted sections were cover-
slipped with fluorescent mounting medium (DAKO, USA). For
chromogenic analysis, secondary antibodies were conjugated
to biotin and visualized using the Avidin/Biotin enzyme
complex (VECTASTAIN ABC system, Vector Labs) coupled with
peroxidase-driven precipitation of diaminobenzidine (DAB).
DAB-labeled sections were dehydrated in alcohol and xylene, and
cover-slipped with DePex mounting medium (BDH Chemicals,
UK). For BrdU labeling, free-floating sections were incubated for
2 h at 65◦C in 50% de-ionized formamide in 0.1 M PBS. The
tissue was rinsed 3× 5 min washes in 0.1 M PBS and acid treated
with 2 M HCL for 30 min at 37◦C. The tissue was then washed in
0.1 M Sodium Borate (pH 8.5) for 15 min and finally rinsed with
3× 5 min washes in 0.1 M PBS.
Primary antibodies and dilution factors were as follows:
mouse anti-APC (1:200; #OPT80, Calbiochem, Germany), rat
anti-BrdU (1:300; #OBT0030, Axyll Laboratories, USA), mouse
anti-Calretinin (1:1000; #7697, Swant, Switzerland), rabbit anti-
Darpp32 (1:500; #AB10518, Millipore, Germany), goat anti-
GDNF (1:200; #AB212NA, R&D, USA), chicken anti-GFP
(1:1000; AB13970, AbCam, USA), rabbit anti-GFP (1:20,000;
#AB13970, AbCam, USA), rabbit anti-Iba1 (1:200; #01919741,
Wako, Japan), goat anti-Meteorin (1:400; #AF3475, R&D, USA),
mouse anti-NeuN (1:200; #MAB377, Millipore, USA), rabbit
anti-Olig2 (1:200; #AB9610, Millipore, USA), rabbit anti-s100β
(1:200; #HPA015768, Sigma−Aldrich, USA).
Imaging
Images of representative co-labeled cells were acquired via 40×
or 63× PL-APO oil immersion objectives (Zeiss) using a Zeiss
780 laser-scanning confocal upright microscope. Representative
overview images of DAB stained sections were acquired
on a Leica DM6000B microscope using a HCX PL 5×/0.5
objective and tiled images aligned using Leica application
suite v3.8 software. NeuN, BrdU, Iba1, Meteorin, GDNF and
GFP immuno-labeled DAB representative images were acquired
on the same microscope using HCX PL 20×/0.5 and HCX
FL PLAN 40×/0.65 objectives (Leica). The brightness and
contrast of individual images was adjusted using the photo
enhancing software Photoshop v7.0 (Adobe) to optimally
represent the immunohistochemistry observed through the
microscope.
Stereology and BrdU+ Cell Density
Estimation
Stereological estimation was used to determine the number
of BrdU+ cells residing in the anterior head of the striatum
across the three treatment groups. For all animals, 30 µm
coronal sections each 360 µm apart (1:12 series) were immuno-
labeled for BrdU. To establish the region of interest, the
rostral boundary of striatum was defined at 1.70 mm anterior
to bregma and the caudal boundary defined at 0.26 mm
anterior to bregma (spanning 0−1440 µm of the anterior
striatum) and delineated by standard anatomical boundaries
(Paxinos and Watson, 1998). Estimates of BrdU-labeled cells
were determined using a fractionator sampling design according
to optical dissector rules (Gundersen et al., 1988; Mayhew,
1991). Counting frame grid dimensions and fractionator x,y
coordinates were determined using the grid overlay program
Stereoinvestigator v7.0 (MicroBrightField, Williston, VT, USA,
used on a microscope, Leica, with a 40× objective, Zeiss).
Guard zones were set at 1 µm (top and bottom) and
BrdU-labeled nuclei quantified within the counting frame
(dimensions used were 90 µm × 90 µm) at periodic intervals
(x = 300 µm, y = 350 µm) in the delineated region of
interest.
To determine BrdU density, volumetric analysis was
conducted to determine the volume of measured striatum.
Striatal volumetric measurements for each brain were achieved
via Cavalieri estimation using the program Stereoinvestigator
v7.0 (MicroBrightField, Williston, VT, USA). The resultant
volume was used to determine the BrdU+ cell density in the
striatum based on the stereological estimation of BrdU+ cells
and reported as BrdU+/mm3. The accuracy of the stereological
estimations was determined by the coefficients of error and
coefficients of variance. Estimations were deemed acceptable if
coefficients were >0.1 (West et al., 1991).
Cell Quantification
In order to assess the phenotype of newborn cells post-lesion
in the striatum, sections from animals sacrificed at 6 weeks
post-lesion were double or triple labeled using fluorescent
immunohistochemical techniques. Sections were stained
with either BrdU/NeuN/Darpp32, BrdU/NeuN/Calretinin,
BrdU/s100β or BrdU/Olig2/APC. Due to the relatively low
number of double and triple labeled cells in the striatum, cells
were manually counted across 3 sections spanning the anterior
head of the striatum (1.70, 1.34, and 0.98 mm anterior to
bregma). An additional rostral striatal section was analyzed
at 0.62 mm from bregma for quantification of BrdU+/s100β+
co-localization.
Using a confocal microscope (Zeiss) and a 20×/0.8 PL-APO
objective (Zeiss), z-stacking, and x−y tile scanning features
were used to capture large 3-dimensional volumes of the
entire striatum for each tissue section. ZEN digital imaging
software (Zeiss) was then used to unambiguously identify all
double/triple labeled BrdU+ cells. When delineating the striatal
volume for analysis, we did not include the highly damaged
area immediately in the vicinity of the QA delivery, which
we found to have a high level of brightly fluorescent non-
specifically labeled cells. All BrdU+ cells initially identified as
co-labeled, were verified by inspection with a 63× PL-APO oil
immersion objective (Zeiss) and orthogonal reconstruction on
the z-axis.
The total number of cells counted across the quantified
striatum (1.70 mm–0.98 mm anterior to bregma) was estimated
by extrapolation based on the series interval (1:12) and the
number of sections counted (3) across the series. In addition
to reporting total cell counts, total cell counts were normalized
to BrdU+ cell density to account for any variability in
these parameters across animals. This normalized result is
reported in the text as a percentage of BrdU+ cell density
(BrdU+/mm3).
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 July 2016 | Volume 10 | Article 177
fncel-10-00177 July 4, 2016 Time: 13:27 # 4
Wright et al. Meteorin Drives Striatal Gliogenesis Post-Injury
For newborn Iba1+ microglia quantification, sections were
stained with BrdU/Iba1. Due to the abundance of BrdU+/Iba1+
cells, one section per animal across treatment groups (n = 3 per
group) was used for quantification (1.34 mm anterior to bregma).
Striatal sections were systematically analyzed from the lateral
ventricle to the site of injury across all animals for consistency.
BrdU+ cells and BrdU+/Iba1+ cells were quantified in this
manner. The resultant BrdU+/Iba1+ cell counts were normalized
to the BrdU+ cell counts obtained from the same experiment and
represented as a percentage.
Statistics
Statistical analysis was conducted using Graphpad Prism v6.0
software. BrdU+ cell density, total cell counts and normalized
cell counts were compared across the three experimental
treatment groups using one-way ANOVA with post hoc
correction (Bonferroni) for multiple comparison. In this study
the data across experimental treatment groups is reported as the
mean± SEM.
RESULTS
Neuronal Cell Loss and Local
Proliferation after Excitotoxic Lesioning
Immunohistochemical labeling of the mature neuronal marker
NeuN showed that injection of QA into the anterior head of the
striatum resulted in a robust loss of neurons (Figures 1A,B). In
some cases we also observed neuronal loss in the overlying cortex,
likely resulting from reflux along the injection tract (not shown).
Labeling for BrdU showed a robust proliferative response during
the first 2 weeks after the lesion (Figures 1C,D). The BrdU+
cells were distributed densely in the immediate vicinity of the
QA injection site, along with what appeared to be some degree
of non-specific labeling, and also more diffusely throughout
the entire striatum. The excitotoxic lesion also resulted in
an inflammatory response that was persistent at 6 weeks, as
demonstrated by a large increase in the density of striatal Iba1+
microglia with a reactive, amoeboid morphology (Figures 1E,F).
Some degree of microglial activation was also observed along
FIGURE 1 | Assessment of lesioning, proliferation, and microglial response 6 weeks after intra-striatal injection of quinolinic acid (QA). Representative
striatal sections of intact and lesioned brains 6 weeks post-lesion (arrow indicates injection site of QA lesion). The boxed area on each section corresponds to the
adjacent 20× image detailing the immuno-labeling. (A) NeuN labeling in intact striatum and (B) 6 weeks post-lesion, detailing loss of neurons in adjacent 20× image.
(C) BrdU labeling of an intact adult striatal section and (D) 6 weeks post lesion. (E) Iba1 staining in intact sections with adjacent 20× image detailing ramified
microglia in the striatum and at (F) 6 weeks post-lesion with reactive microglia illustrated in the adjacent 20× image. Scale bar: 1 mm brain sections (A−F), 200 µm
boxed images (A−F).
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the needle tract in the overlying cortex. Anatomically, the
distribution of microglial activation matched well with the area
of NeuN+ cell loss and increased BrdU+ labeling.
Meteorin Is Highly Diffusible Within the
Striatum When Over-Expressed Using a
Lentiviral Vector
Transduction of the striatum using lentiviral vectors carrying
either GFP (lvGFP), GDNF (lvGDNF) or Meteorin (lvMeteorin)
resulted in robust expression of the transgenes (Figures 2A–F).
At 6 weeks, immunohistochemical analysis showed the expected
cytoplasmic pattern of GFP expression (Figure 2B). The
morphology of the GFP+ cells showed that predominantly
astrocytes were transduced with the vector, although we observed
a smaller population of GFP+ neurons also. Injection of
either lvMeteorin or lvGDNF resulted in a robust expression
throughout the entire striatum (Figures 2C,E). In both cases,
the profile of expression was consistent with that expected
for a secreted protein, including a diffuse labeling pattern
that reduced in intensity with distance from the injection site
(Figures 2D,F).
Over-Expression of Meteorin Did Not
Increase the Number of New Neurons in
the Striatum after Excitotoxic Damage
To assess the impact of Meteorin on neurogenesis in response
to injury, animals were administered BrdU twice daily for
2 weeks to label newborn cells immediately after excitotoxic
damage to the striatum. Animals were perfused for histology
4 weeks later to allow for cell migration and differentiation of
BrdU-labeled cells. Stereological estimation of the total number
of newborn BrdU+ cells in the striatum 6 weeks after injury
showed no significant difference in the density of BrdU+ cells in
the striatum between the lvGFP control (1.8 ± 0.3 x 104 BrdU+
cells/mm3), lvMeteorin (1.2 ± 0.1 × 104 BrdU+ cells/mm3)
and lvGDNF (2.7 ± 0.9 × 104 BrdU+ cells/mm3) groups
(p = 0.67, lvGFP v lvGDNF; p = 0.95, lvGFP v lvMeteorin,
one-way ANOVA, Bonferroni post hoc — Figure 3A), although
the number of BrdU+ cells was notably variable in the lvGDNF
group.
To estimate the number of new neurons generated during
the 2 week BrdU-labeling period after striatal injury, cells
unambiguously immuno-labeled for both BrdU and NeuN were
counted in three coronal sections from each animal 4 weeks after
the final BrdU injection (6 weeks after injury). This involved
a first screening whereby every BrdU+ cell was inspected for
evidence of double labeling, followed by a second level of
screening where double labeling was confirmed by confocal
analysis, including orthogonal reconstruction on the z-axis
(Figures 3E,F).
Comparison of the total BrdU+/NeuN+ cell counts revealed
that the lvGFP control group (86.6 ± 48.4 cells) was not
significantly different in newborn mature neurons compared to
lvMeteorin treated animals (88.5 ± 32.6 cells), but a significant
increase was detected in the lvGDNF group (696 ± 116.2
FIGURE 2 | Validation of lentiviral expression 6 weeks post-lesion. Immunohistochemical analysis at 6 weeks post-injury in animals administered
corresponding lentiviral over-expression constructs across three representative sections (arrow indicates injection site of lentivirus) (A,C,E) corresponding to 1.70,
1.34 and 0.98 mm from bregma, left to right. (A) lvGFP treated animals with GFP immuno-labeling with (B) 40× representative image of GFP+ astrocytic cells in the
striatum. (C) lvMeteorin and (E) lvGDNF treated animals with Meteorin and GDNF immuno-labeling, respectively. (D) Tiled 40× image of lvMeteorin treated animals
and (F) lvGDNF treated animals illustrate diffuse labeling within the striatum. Scale bar: 1 mm (A) analogous for (C,E), 0.1 mm (B,D,F).
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FIGURE 3 | Birth-dating of striatal neurons after quinolinic acid lesion to assess the effect of GDNF and Meteorin on these populations.
(A) Quantification of BrdU+ cell density across treatment groups revealed no significant change in newborn cells in the striatum. (B) Quantification of BrdU+ cells
co-expressing NeuN across treatment groups normalized to BrdU+ cell density revealed lvGDNF increased the number of new neurons in the ipsilateral striatum,
with lvMeteorin having no effect compared to lvGFP controls. (C) Quantification of BrdU+/NeuN+/CalR+ cells normalized to BrdU+ cell density identified lvGDNF
treatment trended toward an increase in this population. (D) CalR+ cells normalized to total BrdU+/NeuN+ cells indicated differentiation into this phenotype is altered
across all newborn neurons. Overview image of BrdU/NeuN/CalR staining (E) and representative orthogonal z-stack confocal images of immuno-labeled
(F) BrdU+/NeuN+/Darpp32− neurons and (G) BrdU+/NeuN+/CalR+ interneurons (arrow). (H) NeuN negative interneurons were also observed as a primary subset
of BrdU+/Calretinin+ cells (arrows). Data represents mean ± SEM. lvGFP n = 7; lvMeteorin n = 6; lvGDNF n = 5. Scale bars: 100 µm. cc, corpus callosum; lv,
lateral ventricle; ac, anterior commissure; CalR, Calretinin.
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cells, p = <1 × 10−4, one-way ANOVA, Bonferroni post
hoc). To account for variability in BrdU dosage and striatal
volume between animals and to assess the proportion of
newborn cells within the striatum acquiring a mature neuronal
phenotype, we normalized the total number of BrdU+/NeuN+
cells to BrdU+ cell density (BrdU+ cells/mm3) to acquire
a percentage (Figure 3B). In lvGFP-treated controls a low
percentage of newborn cells post-lesion obtained a NeuN+
phenotype (5.3 ± 0.2 × 10−2 % of BrdU+ cells/mm3). This
was not significantly different to lvMeteorin-treated animals
(8.5 ± 0.4 × 10−2 % of BrdU+ cells/mm3) but in the
lvGDNF-treated group, an 11-fold increase in the percentage of
BrdU+/NeuN+ cells was detected (47.1± 0.7× 10−2% of BrdU+
cells/mm3, p = < 1 × 10−4, one-way ANOVA, Bonferroni post
hoc; see Figures 3E,F for examples of immunohistochemistry).
Immunohistochemical co-labeling of BrdU+/NeuN+ cells
with markers for striatal projection neurons (Darpp32) or
certain interneuron subtypes (Calretinin) allowed us to assess
the impact of Meteorin or GDNF over-expression on the
phenotype of newly generated neurons following injury.
Although previous studies have indicated a proportion of new
neurons generated after injury acquire a Darpp32+ identity at
(Arvidsson et al., 2002; Parent et al., 2002), we did not observe any
Darpp32+/BrdU+ cells across the three treatment groups. Some
of the BrdU+/NeuN+ cells were found to express Calretinin.
Looking at BrdU+/NeuN+/Calretinin+ cells as a percentage of
total BrdU+ cells/mm3, there was no significant difference across
the three treatment groups although there was a trend toward
a greater proportion in the lvGDNF group (6.5 ± 0.2 × 10−2
% of BrdU+ cells/mm3) compared to the lvGFP control group
(2.4 ± 0.1 × 10−2 % of BrdU+ cells/mm3; p = 0.069, one-
way ANOVA, Bonferroni post hoc) – Figures 3C,G. Similarly,
as a percentage of total newborn neurons (BrdU+/NeuN+ cells)
we observed similar proportions of cells obtaining Calretinin+
phenotype between the lvGFP (20.8 ± 12.7% of cells), lvMeteorin
(19.6 ± 7.7% of cells) and lvGDNF groups (16.7 ± 6.4% of
cells) – Figure 3D. We also observed across all groups numerous
examples of BrdU+/Calretinin+ cells with aspiny neurites that
did not express NeuN within the damaged striatum (Figure 3H).
This may be indicative of a more immature population of
newborn interneurons.
Meteorin Increases Gliogenesis
Following Striatal Damage
Co-labeling of BrdU+ cells with s100β or Olig2 showed that
Meteorin over-expression significantly increased the proportion
of BrdU+ cells with astrocyte and oligodendroglial progenitor
phenotypes, respectively.
Six weeks after injury, quantification of BrdU+/s100β+ cells
in the lvGFP control group showed that, as a fraction of
BrdU+ cell density, 1.3 ± 0.3 % were identified as s100β+
astrocytes (Figures 4A,C). One-way ANOVA showed that the
average fraction of BrdU+ cells co-labeled with s100β was not
significantly different in the lvGDNF group (0.9± 0.3 %) but was
significantly greater in animals treated with lvMeteorin (4.6± 1.5
%; p= 0.048, one-way ANOVA, Bonferroni post hoc; Figure 4C).
To look at the effects of treatment on oligodendrocyte
lineage cells, cells were co-labeled for BrdU+ with the
pan oligodendrocyte marker Olig2 and the post-mitotic
oligodendrocyte marker APC. In all treatment groups we
observed examples of BrdU+/Olig2+ cells that were both
positive and negative for APC expression, indicative of
oligodendrocyte progenitors (BrdU+/Olig2+/APC−) and
more mature oligodendrocytes (BrdU+/Olig2+/APC+),
respectively (Figure 4B). As a percentage of BrdU+ cell density,
lvMeteorin significantly increased the fraction of Olig2+/APC−
oligodendrocyte progenitors (8.1 ± 0.8 %) compared to
lvGFP-treated animals (3.3 ± 1%; p = 0.04, one-way ANOVA,
Bonferroni post hoc), while there was no significant change
between the lvGFP control group and the lvGDNF group
(5.1 ± 2%) – Figure 4D. This equated to a significantly
greater total number of BrdU+/Olig2+/APC− oligodendrocyte
progenitors in the anterior striatum of lvMeteorin treated
animals (8.3 ± 0.8 × 103 cells), compared to the lvGFP
(3.1± 0.9× 103 cells) and lvGDNF groups (6.2± 2.2× 103 cells;
lvGFP v lvMeteorin, p= 0.03, one-way ANOVA, Bonferroni post
hoc).
We then assessed whether the Meteorin mediated increase
in newborn oligodendrocyte progenitors translated to a
greater increase in differentiation toward post-mitotic (APC+)
oligodendrocytes. To do this, we assessed the fraction of
BrdU+/Olig2+ cells that adopted an APC+ phenotype. In the
lvGFP group, an average of 13.4 ± 4.3% of total BrdU+/Olig2+
cells co-expressed APC. Comparison between treatment groups
revealed that there was no significant difference between lvGFP
animals and lvMeteorin (8.0 ± 1.5 %) or lvGDNF animals
(9.9 ± 3.1%; p = 0.71, lvGFP v lvMeteorin; one-way ANOVA,
Bonferroni post hoc) – Figure 4E. This result was consistent
when comparing the average total BrdU+/Olig2+/APC+ cell
number between groups (n.s., p = 0.55, data not shown; lvGFP v
lvMeteorin, one-way ANOVA, Bonferroni post hoc).
We assessed the effects of Meteorin treatment on microglia
proliferation using the microglia marker Iba1 in conjunction
with BrdU (Figure 4F). In the lvGFP treatment group,
36.8 ± 1.8% of BrdU+ cells were Iba1+, indicating that
this is the predominant phenotype of newborn cells post-
injury (Figure 4G). To determine whether Meteorin or GDNF
treatment influenced microglia proliferation after striatal injury,
Iba1/BrdU quantification was conducted across these groups.
Compared to the lvGFP control group, no significant difference
was observed in the percentage of Iba1+/BrdU+ cells in the
lvMeteorin groups (49.3 ± 8.2% of BrdU+ cells; p = 0.27) and
the lvGDNF group (31.1± 5% of BrdU+ cells; p= 0.72; one-way
ANOVA, Bonferroni post hoc) – Figure 4G indicating that these
factors did not influence microglia proliferation post-striatal
injury.
DISCUSSION
These results show that lentiviral delivery of Meteorin to
the damaged striatum leads to robust over-expression of the
diffusible protein resulting in increased gliogenesis but not
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FIGURE 4 | Birth-dating of glial cells in the striatum after QA lesion and assessment of the effect of Meteorin on these populations. (A) Confocal
orthogonal representation of cells in the striatum ipsilateral to lentiviral delivery and lesion confirm double labeling of BrdU+ cells co-stained for either s100β to
identify new born astrocytes or (B) Olig2 and APC to identify newborn OPCs (BrdU+/Olig2+/APC− cells) and mature oligodendrocytes (BrdU+/Olig2+/APC+ cells;
boxed insets detail double and triple labeling of the cells). Newborn glial cells were quantified and represented as a percentage of total BrdU+ cell density. (C) Cell
quantification of BrdU+/s100β+ cells normalized to BrdU+ cell density revealed lvMeteorin-treated animals had significantly more newborn s100β+ astrocytes in the
ipsilateral striatum compared to lvGFP controls. For Oligodendroglial lineages, (D) BrdU+/Olig2+/APC− (OPCs) revealed a significant increase in this population in
lvMeteorin-treated animals compared to lvGFP-treated controls. (E) The percentage of BrdU+/Olig2+ cells that express APC (mature OLs) was assessed and was
not significant between treatment groups. Oligodendrocyte lineage cell quantification was normalized to BrdU+ cell density. (F) Representative BrdU/Iba1 stain with
example BrdU+/Iba1+ cell (boxed) and (G) quantification of BrdU+/Iba1+ cells as a percentage of total BrdU showed no significant difference between treatment
groups. Data represents mean ± SEM, lvGFP n = 7; lvMeteorin n = 6; lvGDNF n = 5 for astrocyte and oligodendrocyte quantification and n = 3 for microglia cell
counts across all groups. Scale bar: 100 µm. OPC, Oligodendrocyte precursor cell; OL, Oligodendrocyte.
neurogenesis in response to striatal injury. Cell proliferation
is a well-established response to acute brain injury (Cavanagh,
1970; Nait-Oumesmar et al., 1999) and it has been convincingly
demonstrated that the majority of the newborn cells are local
microglia (Marty et al., 1991; Amat et al., 1996) which we
have shown accounts for 40% of newborn cells post-injury.
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Importantly, it has also been shown that, following damage to
the striatum, a small proportion of the newborn cells at the
site of injury are neurons that migrate from the adjacent SVZ
(Arvidsson et al., 2001; Parent et al., 2002). This has led to the
idea that augmentation of this neurogenic response might lead to
regenerative therapies for brain repair.
A number of studies have significantly improved the level of
injury-induced striatal neurogenesis through delivery of growth
factors, either as protein infusions (Pencea et al., 2001; Kobayashi
et al., 2006; Ninomiya et al., 2006) or using viral vectors
(Chmielnicki et al., 2004; Benraiss et al., 2012; Yu et al., 2013).
Here we chose to investigate Meteorin in this context based on
previous work showing that it is up-regulated in the striatum
following injury (Jorgensen et al., 2011; Wang et al., 2012;
Lee et al., 2015), can protect striatal neurons from excitotoxic
death (Jorgensen et al., 2011) and is a potent chemokinetic
regulator of migratory doublecortin+ neuroblasts in the striatum
after middle cerebral artery occlusion (MCAO) (Wang et al.,
2012). Although immunohistochemical analysis showed robust
and diffuse over-expression of Meteorin throughout the lesioned
striatum, there was no significant impact on the number of new
striatal neurons generated in the first week after injury relative
to the lvGFP control group. This is in contrast to a similar
study recently reporting that Meteorin infused as a protein over
2 weeks following medial cerebral artery occlusion significantly
increases the number of newborn neurons in the striatum by
around 70% (Wang et al., 2012). The conflicting findings might
be at least partly explained by experimental variables, including
differences in the timing and dose of Meteorin delivery and also
the severity of striatal damage. Notably, however, over-expression
of GDNF using the same lentiviral construct delivered at the same
time relative to injury resulted in a significant increase in the
number of new neurons compared to the Meteorin and control
groups.
We included a GDNF group in order to contextualize the
impact of Meteorin. GDNF is well established as a neurotrophic
factor in models of CNS injury and has previously been shown
to increase the number of newborn cells that survive as mature
neurons in the striatum after striatal injury (Kobayashi et al.,
2006). We observed an 11-fold increase in the number of mature
striatal neurons after striatal injury in GDNF treated animals, but
no significant difference in Meteorin treated animals under the
same experimental conditions. Collectively, the results suggest
that the neurogenic impact of Meteorin following striatal damage
is modest and may be relatively more sensitive to factors related to
timing and dose as well as the nature of the injury. Understanding
the efficacy of neurotrophic proteins in specific injury models is
an important challenge for developing regenerative gene-based
therapies for CNS injury.
Another potential role for neurotrophic factors in modulating
the neurogenic response to injury is through impact on the
differentiation of newborn cells toward therapeutically relevant
cell types — for example striatal projection neurons that can
replace those lost after damage. Based on immunohistochemistry
for Darpp32 6 weeks after lesioning, no examples of new striatal
projection neurons were found across any of the three treatment
groups. However, a number of BrdU+/NeuN+ cells were found
to acquire a Calretinin+ interneuron phenotype. These findings
are consistent with a recent study showing that striatal injury can
facilitate migration of nearby SVZ neuroblasts to the site of injury
but does not influence their original, interneuron differentiation
potential (De Marchis et al., 2007). Neither GDNF nor Meteorin
influenced the fraction of BrdU+/NeuN+ cells to adopt a
Calretinin+ identity. Thus the mechanism underlying greater
neuronal numbers in the GDNF group is likely to be related
in increased survival rather than an influence on differentiation
potential. We also observed many BrdU+/Calretinin+ cells that
did not express NeuN. This may represent a different Calretinin+
phenotype or reflect an immature status of these cells, as has been
shown in studies on staging of protein expression in hippocampal
neurogenesis (Brandt et al., 2003). It is important to note that
the majority of BrdU+/NeuN+ cells did not express Calretinin
or Darpp32. This may reflect an immature phenotype within
the newborn population of striatal neurons. However, previous
studies have shown that insult-mediated neurogenesis in the
striatum produces other interneuron phenotypes characterized
by the markers parvalbumin and neuropeptide Y (Collin et al.,
2005) which may also account for the remaining newborn
neurons.
The most prominent impact of Meteorin over-expression on
newborn cells generated after injury was a significant increase
in the proportion of glial cell types, including s100β+ mature
astrocytes. This is consistent with previous in vitro findings using
primary cultures, where Meteorin has been shown to act through
the Jak-STAT3 pathway to increase astrocyte differentiation
(Nishino et al., 2004; Lee et al., 2010; Sun et al., 2014). We have
previously reported that Meteorin is up-regulated in s100β cells at
the site of injury after excitotoxic lesioning of the striatum. Taken
together, these data suggest that Meteorin may act as a paracrine
signaling molecule to drive gliosis via differentiation in response
to brain damage as opposed to acting as a trophic factor for these
cells. We also looked at microglial phenotype amongst newborn
cells. Iba1+microglia accounted for∼40% of all newborn BrdU+
cells post injury. This is in line with previous literature which
describes an early and rapid proliferative response of microglia
after acute injury in the CNS (Morioka et al., 1993; Topper et al.,
1993; Thored et al., 2009; Taylor and Sansing, 2013). The lack
of impact on the proportion of BrdU+ microglial cells suggests
a specific function for Meteorin in astrocyte differentiation
rather than a broad exacerbation of inflammatory response to
injury.
Interestingly, Meteorin also increased the number of
oligodendrocyte progenitor cells (OPCs). Here we report that
Meteorin significantly increases the number of Olig2+ OPCs
in the striatum following excitotoxic damage. This reveals a
novel biological function for Meteorin in vivo and indicates
therapeutic potential in pathological settings involving loss of
oligodendrocytes—for example the demyelination of neurons
resulting from loss of oligodendrocytes after ischemic stroke
(Pantoni et al., 1996; Dewar et al., 2003). Notably, while the
OPC pool increased in Meteorin treated animals, this did not
translate to an increase in mature APC+ oligodendrocytes. This
may reflect that additional signaling components are required
for maturation in the lesioned striatum and/or an unfavorable
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environment for differentiation. In future studies it will be
valuable to assess and compare the oligogenic effects of Meteorin
with other molecules reported to drive oligodendrogliogenesis
after injury, such as Erythropoietin (Zhang et al., 2010) and
Noggin (Irvin et al., 2008) as well as the mechanism driving
this increase in OPCs to determine whether Meteorin influences
the proliferation and differentiation of this population or
offers trophic support to OPCs. Assessment of the timing and
combinatorial delivery of these molecules may reveal an optimal
approach for increasing both the number of oligodendrocytes
and their capacity for myelination following de-myelinating
injuries. Other valuable future studies to extend on the present
findings would include lineage tracing work aimed at identifying
the cells that respond to MTRN in order to drive gliogenesis.
There is strong evidence to suggest that the neurogenic response
in a variety of striatal injury models, including MCAO (Arvidsson
et al., 2002), QA lesioning (Collin et al., 2005), and traumatic
brain injury (Richardson et al., 2007) is largely provided by the
nearby pool of neurogenic precursors in the SVZ. The origin
of the gliogenic response is less well characterized but may
include both an SVZ component – for example OPCs can be
generated by SVZ precursors and migrate into the striatum
following stroke (Li et al., 2010) – as well as the proliferation of
local parenchymal progenitors or differentiated glia at the site of
injury.
In summary, we demonstrated that Meteorin was able
to increase astrogenesis in the striatum after acute injury
characterized by widespread neuronal cell loss. We also revealed
a novel function for Meteorin in significantly increasing
the number of OPCs post-injury. Interestingly, Meteorin did
not influence the maturation of these cells into mature
oligodendrocytes, suggesting a discrete function on the OPC
population. Meteorin was not effective for augmentation of the
neurogenic response to injury. These findings highlight that
development of strategies for brain-repair based on trophic-
factor delivery will likely require combinatorial approaches,
where specific proteins are targeted to affect the survival and
differentiation of specific cell types.
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